Clinical Trial Update: Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating levetiracetam for neuroleptic-induced tardive dyskinesia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• LEVETIRACETAM (levetiracetam)

Snippet

Sponsor: UCB Pharma | Conditions: Dyskinesia, Medication-induced | Phase 2 | Status: COMPLETED